228 related articles for article (PubMed ID: 33419944)
1. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with
Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA
J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
4. The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.
Bauckneht M; Bertagna F; Donegani MI; Durmo R; Miceli A; De Biasi V; Laudicella R; Fornarini G; Berruti A; Baldari S; Versari A; Giubbini R; Sambuceti G; Morbelli S; Albano D
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1198-1207. PubMed ID: 34012060
[TBL] [Abstract][Full Text] [Related]
5. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
6. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
7. Harmonized pretreatment quantitative volume-based
Kitajima K; Miyoshi Y; Sekine T; Takei H; Ito K; Suto A; Kaida H; Daisaki H; Yamakado K
Hell J Nucl Med; 2020; 23(3):272-289. PubMed ID: 33367302
[TBL] [Abstract][Full Text] [Related]
8. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract][Full Text] [Related]
11. Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
Bauckneht M; Capitanio S; Donegani MI; Zanardi E; Miceli A; Murialdo R; Raffa S; Tomasello L; Vitti M; Cavo A; Catalano F; Mencoboni M; Ceppi M; Marini C; Fornarini G; Boccardo F; Sambuceti G; Morbelli S
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861942
[No Abstract] [Full Text] [Related]
12. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
14. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
Sun Y; Lu P; Yu L
Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
[TBL] [Abstract][Full Text] [Related]
15. Role of volumetric parameters obtained from
Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer.
Ulaner GA; Eaton A; Morris PG; Lilienstein J; Jhaveri K; Patil S; Fazio M; Larson S; Hudis CA; Jochelson MS
Cancer Med; 2013 Oct; 2(5):725-33. PubMed ID: 24403238
[TBL] [Abstract][Full Text] [Related]
17. Radiomics analysis of pre-treatment [
van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients.
Zschaeck S; Li Y; Lin Q; Beck M; Amthauer H; Bauersachs L; Hajiyianni M; Rogasch J; Ehrhardt VH; Kalinauskaite G; Weingärtner J; Hartmann V; van den Hoff J; Budach V; Stromberger C; Hofheinz F
PLoS One; 2020; 15(7):e0236841. PubMed ID: 32730364
[TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing
Reinert CP; Gatidis S; Sekler J; Dittmann H; Pfannenberg C; la Fougère C; Nikolaou K; Forschner A
Cancer Imaging; 2020 Jul; 20(1):44. PubMed ID: 32631431
[TBL] [Abstract][Full Text] [Related]
20. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]